EDIT
Editas Medicine, Inc.2.5100
+0.0700+2.87%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
245.02MP/E (TTM)
-Basic EPS (TTM)
-2.35Dividend Yield
0%Recent Filings
8-K
Q3 loss narrows, EDIT-401 advances
Editas Medicine reported Q3 2025 results, slashing net loss to $25.1M from $62.1M year-over-year, fueled by $7.5M collaboration revenue and sharp R&D cuts post reni-cel discontinuation. Cash stands at $165.6M, stretched to Q3 2027 via ATM sales. EDIT-401 preclinical data shone: over 90% LDL-C drop in primates. IND/CTA on track for mid-2026.
10-Q
Q3 FY2025 results
Editas Medicine posted Q3 revenue of $7.5M from a BMS milestone, up sharply from $0.1M y/y, yet operating loss narrowed to $24.5M from $65.7M as R&D expenses plunged 58% post-reni-cel discontinuation and 65% headcount cut. Cash burn slowed; operating cash use hit $128.9M YTD versus $159.5M y/y, bolstered by $25.8M ATM equity raises, leaving $165.6M in cash and equivalents. Restructuring tallied $66.9M YTD, including $52.3M contract costs and $3.7M impairments. DRI liability for Vertex royalties stands at $59.1M after $6.6M interest. Cash lasts into Q3 2027. Patent interferences cloud IP freedom.
8-K
EDIT-401 hits ≥90% LDL-C drop
Editas Medicine unveiled in vivo preclinical proof-of-concept for EDIT-401 at the ESGCT Congress on October 9, 2025, showing ≥90% LDL-C reductions in non-human primates within 48 hours of a single dose and durable effects over three months in mice. The CRISPR/Cas9 strategy with LNP delivery upregulates LDLR via 3' UTR disruption, yielding ≥6-fold liver protein increases. Data bolsters conviction in this one-time therapy approach.
8-K
EDIT-401 nominated as lead candidate
Editas Medicine nominated EDIT-401, an in vivo gene-editing therapy targeting LDLR to slash LDL-C levels, as its lead development candidate on September 2, 2025. Preclinical non-human primate studies showed ~90% mean LDL-C reduction after a single dose, sustained for a month, with six-fold LDLR protein boost and no adverse effects. EDIT-401 pivots resources from HSC programs. Cash funds operations into Q2 2027. IND/CTA by mid-2026.
8-K
Q2 loss narrows; in vivo advances
Editas Medicine reported Q2 2025 net loss of $53.2 million, down from $67.6 million last year, as R&D expenses dropped $38 million to $16.2 million post reni-cel discontinuation, offset by $26.1 million restructuring charges. Cash stands at $178.5 million, funding operations into Q2 2027. Plans to select lead in vivo candidate in September; BMS collaboration triggered milestone on CD19 IND/CTA acceptance. Preclinical data validated gene upregulation strategy.
IPO
Employees
Sector
Industry
ALT
Altimmune, Inc.
5.03-0.25
BEAM
Beam Therapeutics Inc.
26.76-0.07
CRSP
CRISPR Therapeutics AG
55.97-0.28
DTIL
Precision BioSciences, Inc.
4.82+0.02
GNTA
Genenta Science S.p.A.
1.32-0.10
IMA
ImageneBio, Inc.
6.25+0.08
MGX
Metagenomi, Inc.
1.71+0.10
NTLA
Intellia Therapeutics, Inc.
9.12-0.02
PRME
Prime Medicine, Inc.
3.88-0.16
RVMD
Revolution Medicines, Inc.
77.56-1.44